Anavex Life Sciences announces positive Phase 2b/3 trial results for ANAVEX2-73 in Alzheimer's disease

ANAVEX LIFE SCIENCES CORP.

Trial met primary endpoints ADAS-Cog and ADCS-ADL with statistically significant results (p=0.033 and p=0.0255).
Key secondary endpoint CDR-SB also met (p=0.040), showing 27% reduction in clinical decline.
Patients treated with ANAVEX2-73 were 84% more likely to have improved cognition vs placebo (Odds Ratio=1.84).
ANAVEX2-73 demonstrated 45% reduction in cognitive decline measured by ADAS-Cog compared to placebo.
Company plans to meet with regulatory authorities to discuss next steps for approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.